Remarkably, none of the tested Bcl-2 family inhibitors reduced CD4+/CD8+ T cell viability in RA patients, whereas high concentrations of Mcl-1 inhibition led to an approximately 30% reduction in CD4+ T cell viability in SLE. This evidence concerns the gene BCL2 and systemic lupus erythematosus.